Members
- Teresa Amaral (Chair)
- Reinhard Dummer (Chair)
- Petr Arenberger
- Ana-Maria Forsea
- Christoffer Gebhardt
- Céleste Lebbé
- Josep Malvehy
- Ketty Peris
- Susana Puig
- Caroline Robert
- Philippe Saiag
Scope and objectives
The EADO Task Force aims to streamline cooperation between EADO researchers, academic centers and the industry involved in biomarkers and innovative therapies worldwide. The EADO TF of Biomarkers aims to facilitate the discovery of new biomarkers in skin cancer and participate in the study and clinical validation.
The group’s primary objectives are:
- to facilitate cooperative research in biomarkers with skin cancer centers
- to collaborate with the industry for the evaluation, validation, and market approval of biomarker in skin cancers
- to elaborate reviews and position papers on biomarkers in skin cancer
- to participate in the elaboration EADO Guidelines on biomarkers in skin cancer
Launch of a Joint EADO–EUMelaReg ctDNA Project
On behalf of EADO, we are pleased to announce the launch of a joint EADO–EUMelaReg project aimed at integrating circulating tumor DNA (ctDNA) into routine melanoma follow-up. The project will evaluate the clinical utility of ctDNA assessed using Oncobit’s CE-IVDR–marked digital PCR solution to detect relapse and to complement or potentially replace established monitoring approaches. By closely reflecting real-world clinical practice and leveraging the strengths of the EUMelaReg registry, this initiative seeks to advance precision monitoring in melanoma care.
Key aspects of the project include:
- ctDNA testing would be conducted as part of clinical routine, similar to established markers such as LDH and S100.
- This is permissible as a CE-marked (IVDR-compliant) test, OncobitTM PM, is used.
- When performed within routine diagnostics, results can be reported directly to patients.
- All resulting clinical and ctDNA data can subsequently be entered into the EUMelaReg registry.
- A consolidated readout from the registry can then be performed at a dedicated time point (similar to other EUMelaReg publications).
Please reach out to Prof. Dr. Reinhard Dummer or Dr. Claudia Scheckel for more information.